Tuesday, February 3, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Nel ASA Shares Face Pressure as Hydrogen Specialist Reports Steep Order Decline

Robert Sasse by Robert Sasse
October 29, 2025
in Earnings, European Markets, Hydrogen
0
Nel ASA Stock
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Norwegian hydrogen technology company Nel ASA finds itself navigating turbulent waters following the release of its third-quarter 2025 results. The company’s financial performance reveals a concerning contraction in order activity, casting a shadow over its near-term growth trajectory despite some operational improvements.

Financial Performance Highlights

Nel’s revenue for the third quarter of 2025 declined significantly, falling 17 percent to 303 million Norwegian kroner. While the top-line figure showed weakness, the company demonstrated progress on operational efficiency metrics. The EBITDA loss narrowed substantially to 37 million kroner, a marked improvement from the 90 million kroner loss recorded in the same period last year. Similarly, the net loss contracted from 115 million kroner to 85 million kroner.

The company maintains a solid liquidity position with 1.757 billion kroner in cash reserves, providing a financial buffer during this challenging market phase.

Order Book Concerns Deepen

The most alarming aspect of Nel’s quarterly report comes from its order activity. New order intake plummeted by 64 percent to just 57 million kroner, while the total order backlog shrank by 47 percent year-over-year to 984 million kroner. Even compared to the previous quarter, the order situation deteriorated by 21 percent.

This decline in orders presents a puzzling contrast to the company’s continued involvement in over 500 megawatts of FEED studies. The critical question facing management is why these preliminary studies are failing to convert into firm contracts.

Should investors sell immediately? Or is it worth buying Nel ASA?

Diverging Segment Performance

An examination of Nel’s business segments reveals a mixed operational picture:

  • PEM Electrolyzers: Revenue declined 15 percent, though the segment’s EBITDA loss improved to 34 million kroner from 57 million kroner in the prior year period
  • Alkaline Electrolyzers: Revenue decreased 17 percent, but the segment achieved positive EBITDA of 26 million kroner, indicating operational enhancements

Strategic Partnerships and Future Outlook

Nel’s strategic alliances with industry giants General Motors, Reliance, and Samsung E&A remain intact, providing some stability amid the current challenges. However, the broader hydrogen sector continues to face headwinds including project delays and tempered demand, with Nel squarely positioned within this difficult environment.

The company’s recovery hopes appear pinned on its next-generation technology platform. CEO Håkon Volldal emphasized the dual focus on commercializing new technologies while preserving cash. The planned launch of the pressurized alkaline platform in the first half of 2026 promises substantially reduced capital investment requirements and improved energy efficiency.

Whether this forthcoming PEM solution can deliver the necessary performance improvements to revitalize order growth remains the decisive factor for the hydrogen pioneer’s future trajectory.

Ad

Nel ASA Stock: Buy or Sell?! New Nel ASA Analysis from February 3 delivers the answer:

The latest Nel ASA figures speak for themselves: Urgent action needed for Nel ASA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 3.

Nel ASA: Buy or sell? Read more here...

Tags: Nel ASA
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

SpringWorks Therapeutics Stock
European Markets

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

February 3, 2026
Commerce Stock
Analysis

Commerce Bancshares Surpasses Market Forecasts in Year-End Report

February 3, 2026
Genworth Stock
Analysis

Strategic Moves at Genworth Financial Ahead of Earnings

February 3, 2026
Next Post
Asml Stock

ASML Shares Surge on Strong Earnings and AI Integration Strategy

Metaplanet Stock

Japanese Firm Metaplanet Pioneers Bitcoin-Backed Share Buyback

CureVac Stock

CureVac Shareholders Face Critical Deadline in BioNTech Takeover Bid

Recommended

iShares MSCI India ETF Stock

India’s Equity Surge: The iShares MSCI India ETF Capitalizes on Economic Momentum

3 months ago
Biotechnology Trading online

Evogene Ltd Reports Record Revenue Growth in 2023 Expands Partnerships and Plans Strategic Shift

2 years ago
Fiserv Stock

Fiserv Shares Under Pressure as Analyst Sentiment Shifts

4 months ago
Eutelsat Stock

Eutelsat’s Strategic Moves Set Stage for Crucial Shareholder Vote

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

BancFirst Strengthens Regional Footprint with Acquisition Finalization

iShares MAFE ETF Reaches Fresh 52-Week Peak

PriceSmart Kicks Off Fiscal 2026 with Robust Sales and Expansion Ambitions

Smurfit WestRock’s First Post-Merger Strategy Reveal Approaches

Merger Advances as Gold Resource Corporation Resumes Key Mine Operations

iRobot’s New Chapter: A Private Future After Failed Amazon Deal and Bankruptcy

Trending

SpringWorks Therapeutics Stock
European Markets

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

by Andreas Sommer
February 3, 2026
0

Six months after finalizing its acquisition, Merck KGaA is hitting significant milestones in its integration of SpringWorks...

Commerce Stock

Commerce Bancshares Surpasses Market Forecasts in Year-End Report

February 3, 2026
Genworth Stock

Strategic Moves at Genworth Financial Ahead of Earnings

February 3, 2026
BancFirst Stock

BancFirst Strengthens Regional Footprint with Acquisition Finalization

February 3, 2026
iShares MSCI EAFE ETF Stock

iShares MAFE ETF Reaches Fresh 52-Week Peak

February 3, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum
  • Commerce Bancshares Surpasses Market Forecasts in Year-End Report
  • Strategic Moves at Genworth Financial Ahead of Earnings

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com